SAN DIEGO, Dec. 13, 2017 /PRNewswire/ -- Genalyte, Inc.
announced today that CEO and founder Cary
Gunn will publicly debut the company's state of the art
diagnostic testing approach in San
Francisco, CA during the 36th annual J.P. Morgan
Healthcare Conference, January 8-11,
2018.
Genalyte will create a patient testing lab station to coincide
with leading health care conferences occurring in San Francisco throughout the week. Conference
attendees, investors and members of the media will have the
opportunity to personally experience the company's comprehensive
blood testing service and rapid results delivery through free,
voluntary participation.
Genalyte employs a cloud-based laboratory model to test and
deliver high-quality, diagnostic results in the doctor's
office. Results are available in approximately 15 minutes,
allowing physicians to make informed diagnosis and treatment
decisions while the patient is still present. Additional details on
test location and times will be provided prior to the
conference.
Genalyte's state of the art technology moves data—not blood—to
transform the standard of care into a service that dramatically
improves patient safety and outcomes. By digitizing blood
samples, and moving data to a cloud lab facility, Genalyte delivers
rapid, accurate results that drive better outcomes, lowers the
overall cost of care and improves the patient experience.
About Genalyte
Genalyte's mission is to empower
doctors and patients to make better decisions that improve
outcomes, lower overall costs, and make the diagnostics experience
more effective. We employ a cloud-based laboratory service to
bring diagnostic testing into the physician's office. Results
are returned in approximately 15 minutes, eliminating the need for
separate trips to the lab and waiting for results. For more
information, please visit: www.genalyte.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/genalyte-to-unveil--exhibit-its-diagnostic-cloud-lab-during-the-36th-annual-jp-morgan-healthcare-conference-300570726.html
SOURCE Genalyte, Inc.